androstanediol (5 β A), and the endogenous reference 5 β -pregnanediol (5 β P) in the frame of an excretion study following oral ingestion of testosterone initially and 13 h later by a healthy, male Caucasian volunteer ...

"Similarly to the T/E ratio, the δ^{13} C-values of the four T metabolites decrease rapidly after T administration with a difference of about 5‰ with respect to the endogenous reference 5 β P ...

"our results suggest that measurements of 5 β -androstandediol δ -values allow the detection of a testosterone ingestion over a longer period than other T metabolites δ^{13} C-values."

Therefore, if an athlete used exogenous testosterone, his measured difference

 5β Adiol - 5β Pdiol should be greater that his measured difference 5α Adiol - 5β Pdiol. In

the Landis sample, this is not even close to the case: LNDD reported the following

corrected values:

For the "A" sample:

5βAdiol - 5βPdiol: -2.15‰ 5αAdiol - 5βPdiol: -6.14‰

For the "B" sample:

5βAdiol - 5βPdiol: -2.65‰ 5αAdiol - 5βPdiol: -6.39‰

Had Landis used exogenous testosterone, the Maitre publication indicates that his 5β Adiol - 5β Pdiol should be at or greater than -6‰, given the measurement of 5α Adiol - 5β Pdiol. At a minimum, one would expect the 5β Adiol - 5β Pdiol to exceed the threshold of 3‰, which it does not. The only conclusion that can be drawn from the fact that the 5β Adiol - 5β Pdiol measurement is well below the threshold, when the WADA-accredited laboratories state that this measurement is the **best indicator** of exogenous testosterone administration, is that Floyd Landis did not use exogenous testosterone.